Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Operating Leases (2019 - 2025)

Abeona Therapeutics (ABEO) has 7 years of Operating Leases data on record, last reported at $4.3 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 25.04% year-over-year to $4.3 million; the TTM value through Sep 2025 reached $4.3 million, up 25.04%, while the annual FY2024 figure was $3.3 million, 25.9% down from the prior year.
  • Operating Leases reached $4.3 million in Q3 2025 per ABEO's latest filing, up from $4.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.5 million in Q2 2022 and bottomed at $3.0 million in Q2 2024.
  • Average Operating Leases over 5 years is $5.1 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Operating Leases: skyrocketed 80.75% in 2022, then tumbled 48.72% in 2023.
  • A 5-year view of Operating Leases shows it stood at $7.6 million in 2021, then fell by 22.57% to $5.9 million in 2022, then decreased by 24.8% to $4.4 million in 2023, then dropped by 25.9% to $3.3 million in 2024, then skyrocketed by 30.41% to $4.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $4.3 million in Q3 2025, $4.0 million in Q2 2025, and $4.1 million in Q1 2025.